AU2013349721B2 - Prognostic method for individuals with prostate cancer - Google Patents

Prognostic method for individuals with prostate cancer Download PDF

Info

Publication number
AU2013349721B2
AU2013349721B2 AU2013349721A AU2013349721A AU2013349721B2 AU 2013349721 B2 AU2013349721 B2 AU 2013349721B2 AU 2013349721 A AU2013349721 A AU 2013349721A AU 2013349721 A AU2013349721 A AU 2013349721A AU 2013349721 B2 AU2013349721 B2 AU 2013349721B2
Authority
AU
Australia
Prior art keywords
category
pca
snppc
composite value
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013349721A
Other languages
English (en)
Other versions
AU2013349721A1 (en
Inventor
Martin Eklund
Henrik Gronberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A3p Biomedical AB
Original Assignee
A3p Biomedical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A3p Biomedical AB filed Critical A3p Biomedical AB
Publication of AU2013349721A1 publication Critical patent/AU2013349721A1/en
Application granted granted Critical
Publication of AU2013349721B2 publication Critical patent/AU2013349721B2/en
Assigned to A3P BIOMEDICAL AB reassignment A3P BIOMEDICAL AB Request for Assignment Assignors: PHADIA AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
AU2013349721A 2012-11-20 2013-11-20 Prognostic method for individuals with prostate cancer Active AU2013349721B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1251310 2012-11-20
SE1251310-7 2012-11-20
SE1350602-7 2013-05-16
SE1350602 2013-05-16
PCT/EP2013/074270 WO2014079874A1 (en) 2012-11-20 2013-11-20 Prognostic method for individuals with prostate cancer

Publications (2)

Publication Number Publication Date
AU2013349721A1 AU2013349721A1 (en) 2015-05-28
AU2013349721B2 true AU2013349721B2 (en) 2019-03-28

Family

ID=49713059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013349721A Active AU2013349721B2 (en) 2012-11-20 2013-11-20 Prognostic method for individuals with prostate cancer

Country Status (8)

Country Link
US (2) US10428385B2 (enExample)
EP (1) EP2922970B1 (enExample)
JP (1) JP2016508026A (enExample)
AU (1) AU2013349721B2 (enExample)
CA (1) CA2891394C (enExample)
ES (1) ES2694409T3 (enExample)
RU (1) RU2669809C2 (enExample)
WO (1) WO2014079874A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3312749B1 (en) 2012-03-05 2024-05-01 OY Arctic Partners AB Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
WO2014079865A1 (en) 2012-11-20 2014-05-30 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
JP6625061B2 (ja) * 2014-03-11 2019-12-25 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 固形腫瘍癌を検出する方法
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
FI3123381T3 (fi) 2014-03-28 2023-11-27 Opko Diagnostics Llc Eturauhassyövän diagnosointiin liittyviä koostumuksia ja menetelmiä
CA2979559A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
SG11201708289TA (en) * 2015-04-29 2017-11-29 Opko Diagnostics Llc Compositions and methods for active surveillance of prostate cancer
JP6570929B2 (ja) * 2015-09-08 2019-09-04 国立研究開発法人農業・食品産業技術総合研究機構 特性推定モデル生成装置および方法、解析対象の特性推定装置および方法
WO2018141828A1 (en) * 2017-02-01 2018-08-09 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
AU2019210320A1 (en) * 2018-01-22 2020-07-23 Phadia Ab Method for the harmonization of assay results

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
CA2677994A1 (en) * 2007-02-07 2008-08-14 Decode Genetics Ehf. Genetic variants contributing to risk of prostate cancer
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) * 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
WO2013172779A2 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
WO2014079865A1 (en) 2012-11-20 2014-05-30 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. AMIN AL OLAMA ET AL, HUMAN MOLECULAR GENETICS, (2012-10-12), vol. 22, no. 2, doi:10.1093/hmg/dds425, ISSN 0964-6906, pages 408 - 415 *
A. KARIM KADER ET AL, EUROPEAN UROLOGY, (2012-05-11), vol. 62, no. 6, doi:10.1016/j.eururo.2012.05.006, ISSN 0302-2838, pages 953 - 961 *
MARKUS ALY ET AL, EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 60, no. 1, doi:10.1016/J.EURURO.2011.01.017, ISSN 0302-2838, (2011-01-08), pages 21 - 28, (2011-01-11) *
MATTHEW P. JOHNSON ET AL, "Genome-Wide Association Scan Identifies a Risk Locus for Preeclampsia on 2q14, Near the Inhibin, Beta B Gene", PLOS ONE, (2012-03-14), vol. 7, no. 3, doi:10.1371/journal.pone.0033666, ISSN 1932-6203, page e33666 *
R. J. KLEIN ET AL, CANCER PREVENTION RESEARCH, (2010-04-27), vol. 3, no. 5, doi:10.1158/1940-6207.CAPR-09-0206, ISSN 1940-6207, pages 611 - 619 *

Also Published As

Publication number Publication date
EP2922970B1 (en) 2018-08-08
AU2013349721A1 (en) 2015-05-28
US10428385B2 (en) 2019-10-01
CA2891394A1 (en) 2014-05-30
EP2922970A1 (en) 2015-09-30
WO2014079874A1 (en) 2014-05-30
JP2016508026A (ja) 2016-03-17
ES2694409T3 (es) 2018-12-20
CA2891394C (en) 2023-03-14
US20200010912A1 (en) 2020-01-09
RU2015124008A (ru) 2017-01-10
US20150284804A1 (en) 2015-10-08
RU2669809C2 (ru) 2018-10-16

Similar Documents

Publication Publication Date Title
AU2013349801B2 (en) Method for indicating a presence or non-presence of aggressive prostate cancer
AU2013349721B2 (en) Prognostic method for individuals with prostate cancer
RU2720148C9 (ru) Способ обнаружения солидной злокачественной опухоли
US20150094221A1 (en) Method for Indicating the Presence or Non-Presence of Prostate Cancer
JP2022179483A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
CN105051206B (zh) 用于指示侵袭性前列腺癌的存在或不存在的方法
HK1215594B (en) Method for indicating a presence or non-presence of aggressive prostate cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: A3P BIOMEDICAL AB

Free format text: FORMER OWNER(S): PHADIA AB